Phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+metastatic breast cancer (HER2CLIMB-05, trial in progress)

被引：0
|
作者：
Kiver, Verena [1 ]
Hamilton, Erika [2 ]
Tsurutani, Junji [3 ]
Curigliano, Giuseppe [4 ]
Martin, Miguel [5 ]
O'sullivan, Ciara [6 ]
Sohn, Joo Hyuk [7 ]
Tryfonidis, Konstantinos [8 ]
Santarpia, Libero [9 ]
Yang, Shan [9 ]
Dieras, Veronique [10 ]
机构：
[1] Charite Univ Med Berlin, Berlin, Germany
[2] Sarah Cannon Res Inst, Nashville, TN USA
[3] Showa Univ, Adv Canc Translat Res Inst, Tokyo, Japan
[4] Univ Milan, European Inst Oncol, IRCCS, Milan, Italy
[5] Hosp Gen Univ Gregorio Maranon, Madrid, Spain
[6] Mayo Clin, Rochester, MN USA
[7] Yonsei Canc Ctr, Seoul, South Korea
[8] Merck & Co Inc, Rahway, NJ USA
[9] Seagen Inc, Bothell, WA USA
[10] Eugene Marquis Ctr, Rennes, France
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2024年 / 47卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
762
引用
收藏
页码：39 / 39
页数：1
相关论文
共 50 条
  • [41] COST-EFFECTIVENESS ANALYSIS OF NOVEL THERAPIES FOR HER2+METASTATIC BREAST CANCER: [FAM-] TRASTUZUMAB DERUXTECAN VERSUS TUCATINIB TRASTUZUMAB AND CAPECITABINE COMBINATION
    Vondeling, G.
    Palaka, E.
    Livings, C.
    Naik, J.
    Sullivan, W.
    VALUE IN HEALTH, 2020, 23 : S433 - S434
  • [42] MOUNTAINEER-03: Phase III study of tucatinib, trastuzumab, and mFOLFOX6 as first-line treatment in HER2+metastatic colorectal cancer (trial in progress)
    Andre, T.
    Bekaii-Saab, T.
    Tabernero, J.
    Siena, S.
    Yoshino, T.
    Norwood, K. G.
    Adelberg, D. E.
    Ward, J.
    Yang, S.
    Strickler, J. H.
    Van Cutsem, E.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S734 - S735
  • [43] Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
    Swain, Sandra M.
    Baselga, Jose
    Kim, Sung-Bae
    Ro, Jungsil
    Semiglazov, Vladimir
    Campone, Mario
    Ciruelos, Eva
    Ferrero, Jean-Marc
    Schneeweiss, Andreas
    Heeson, Sarah
    Clark, Emma
    Ross, Graham
    Benyunes, Mark C.
    Cortes, Javier
    NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (08): : 724 - 734
  • [44] Updated results of tucatinib vs placebo added to trastuzumab and capecitabine for patients with previously treated HER2-positive metastatic breast cancer with brain metastases (HER2CLIMB)
    Lin, Nancy U.
    Murthy, Rashmi K.
    Abramson, Vandana
    Anders, Carey
    Bachelot, Thomas
    Bedard, Philippe
    Borges, Virginia
    Cameron, David
    Cameron, David
    Carey, Lisa
    Chien, A. Jo
    Curigliano, Giuseppe
    DiGiovanna, Michael
    Gelmon, Karen
    Hortobagyi, Gabriel
    Hurvitz, Sara
    Krop, Ian
    Loi, Sherene
    Loibl, Sibylle
    Mueller, Volkmar
    Oliveira, Mafalda
    Paplomata, Elisavet
    Pegram, Mark
    Slamon, Dennis
    Zelnak, Amelia
    Ramos, Jorge
    Feng, Wentao
    Winer, Eric
    CANCER RESEARCH, 2022, 82 (04)
  • [45] Multicenter phase 2 trial of varlitinib versus lapatinib in combination with capecitabine in patients with HER2+metastatic breast cancer (MBC) who failed prior trastuzumab therapy
    Lee, S. C.
    Chen, S-C.
    Dai, M-S.
    Lee, G. E.
    Liu, C-L.
    Chan, A.
    Chang, H-K.
    Tseng, L-M.
    Chay, W. Y.
    Chow, L. W. C.
    Peneyra, J. L.
    Rau, K-M.
    Wang, H-C.
    Guancia, A. A.
    Head, M.
    Chiu, J. W. Y.
    Robinson, B.
    Lindmark, B.
    McIntyre, N.
    Hsieh, C-Y.
    ANNALS OF ONCOLOGY, 2017, 28 : 30 - 30
  • [46] MOUNTAINEER-03: Phase 3 study of tucatinib, trastuzumab, and mFOLFOX6 as first-line treatment in HER2+metastatic colorectal cancer-Trial in progress.
    Bekaii-Saab, Tanios S.
    Van Cutsem, Eric
    Tabernero, Josep
    Siena, Salvatore
    Yoshino, Takayuki
    Nakamura, Yoshiaki
    Raghav, Kanwal Pratap Singh
    Cercek, Andrea
    Heinemann, Volker
    Adelberg, David E.
    Ward, James Edward
    Yang, Shan
    Andre, Thierry
    Strickler, John H.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : TPS261 - TPS261
  • [47] The association of centromere amplification and response to trastuzumab in HER2+metastatic breast cancer
    Andrieu, Charlotte
    Al-Sultan, Dalal
    Ivers, Laura
    Pina, Jose Javier Berenguer
    Skrobo, Darko
    Ballot, Josephine
    Eustace, Alex J.
    Gullo, Giuseppe
    Crown, John
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [48] Efficacy, safety and tolerability of dual monoclonal antibody therapy with pertuzumab plus trastuzumab in HER2+metastatic breast cancer patients previously treated with trastuzumab
    Baselga, J.
    Imadalou, K.
    Paton, V
    Gray, D.
    Swain, S.
    CANCER RESEARCH, 2009, 69 (02) : 243S - 244S
  • [49] A phase II trial with trastuzumab and pertuzumab in patients with HER2-overexpressed locally advanced and metastatic breast cancer
    Walshe, Janice M.
    Denduluri, Neelima
    Berman, Arlene W.
    Rosing, Douglas R.
    Swain, Sandra M.
    CLINICAL BREAST CANCER, 2006, 6 (06) : 535 - 539
  • [50] HER2CLIMB-04: Phase II trial of tucatinib plus trastuzumab deruxtecan in patients with HER2+unresectable locally-advanced or metastatic breast cancer with and without brain metastases
    Hamilton, E.
    Ramos, J.
    Feng, W.
    Krop, I.
    ANNALS OF ONCOLOGY, 2021, 32 : S76 - S76
12345